Clinical stage gene editing company Precision BioSciences (Nasdaq:DTIL) announced on Monday that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PBGENE-HBV, a gene editing therapy designed to eliminate the root cause of chronic hepatitis B.
PBGENE-HBV is the first investigational in vivo gene editing therapy approved to enter clinical trials for this condition in the United States.
With this clearance, Precision will expand its ongoing Phase 1 ELIMINATE-B study to the US, adding Massachusetts General Hospital to clinical sites already active in Moldova, Hong Kong and New Zealand. The trial is evaluating PBGENE-HBV's ability to eliminate cccDNA and inactivate integrated hepatitis B virus DNA in hepatocytes.
The first cohort of patients has been enrolled, with additional doses being administered at the initial dose level of 0.2 mg/kg. The company plans to escalate to a higher dose level in a second cohort to determine the optimal dosing strategy.
Precision expects to further expand the trial to the UK and continue recruiting a genetically diverse patient population. The company has reported promising early safety and efficacy data and plans to share further clinical results throughout 2025.
Sebela Pharmaceuticals' tegoprazan Phase 3 TRIUMpH studies in GERD achieve positive topline results
BioArctic secures European substance patent for Parkinson's drug candidate exidavnemab
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
1Cell.Ai launches OncoIncytes multi-modal cancer diagnostic panel
Viatris seeks Japanese approval for Effexor for generalised anxiety disorder
Kelun-Biotech's SKB518 granted IND clearance by US FDA
WuXi Biologics completes PPQ campaign at 15,000L production line in Hangzhou
SparX to present Phase 1 clinical update during AACR 2025
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
Clario partners with AWS on advancing clinical data analysis with generative AI
Mezzion Pharmaceuticals welcomes dedicated ICD-10 diagnosis codes for Fontan-associated conditions
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025